CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 436 enrolled
Drug / intervention
anti spasmodic agents +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01404923
NCT01404923Phase 4Completed
CompareCT.gov

Assessment of On-demand MeteoSpasmyl® Use Effectiveness in Irritable Bowel Syndrome

Laboratoires Mayoly Spindler·interventional·Posted Jul 28, 2011·Updated Nov 4, 2014

In Brief

A Phase 4 clinical trial evaluating anti spasmodic agents and alverine citrate, simeticone for Irritable Bowel Syndrome. Completed, enrolled 436 participants.

Detailed Summary

The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: * Strategy A = MeteoSpasmyl®, on-demand therapy * Strategy B = standard of care chosen by the physician

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 28, 2011
Enrollment StartDec 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.9 years ago

Interventions

anti spasmodic agentsdrug

best standard of care prescriptions

alverine citrate, simeticonedrug

on-demand therapy